{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:26:10Z","timestamp":1772252770638,"version":"3.50.1"},"reference-count":28,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC81800717"],"award-info":[{"award-number":["NSFC81800717"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["20180530039"],"award-info":[{"award-number":["20180530039"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["NSFC81800717"],"award-info":[{"award-number":["NSFC81800717"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["20180530039"],"award-info":[{"award-number":["20180530039"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Penile squamous cell carcinoma (PSCC) is a rare disease. The treatment options for advanced penile cancer are often limited, and the prognosis remains poor. We reported a 52-year-old male recurrent and metastatic PSCC patient with high PD-L1 expression (90%) and TMB (14.4 muts\/Mb). He had undergone penectomy, bilateral inguinal lymph node dissection, and excision of the abdominal wall mass. Despite cisplatin-based concurrent chemoradiotherapy and sequential chemotherapy with docetaxel plus cisplatin then being carried out, the carcinoma still progressed. The patient then obtained progression-free survival with continuous sintilimab, although he experienced the new onset of ICI-induced diabetes after 24 cycles of sintilimab and required sustained insulin treatment. He had negative type 1 diabetes-associated autoantibodies and the susceptible HLA genotype DR3-DQ2 haplotype. This is the first patient with radiation and multichemorefractory PSCC who has obtained the remarkable anti-tumor effect of partial regression exceeding 32 months during continuous sintilimab and anlotinib treatment.<\/jats:p>","DOI":"10.3390\/curroncol29110632","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T12:29:45Z","timestamp":1666700985000},"page":"7987-7993","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sintilimab-Induced Diabetic Ketoacidosis in a Patient with Radiation and Multichemorefractory Penile Cancer: A Case Report and Literature Review"],"prefix":"10.3390","volume":"29","author":[{"given":"Chuan","family":"Lv","sequence":"first","affiliation":[{"name":"Department of Endocrinology, People\u2019s Hospital of China Medical University, The People\u2019s Hospital of Liaoning Province, Shenyang 110016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Can","family":"Wu","sequence":"additional","affiliation":[{"name":"Endoscopy Department, The First Affiliated Hospital of China Medical University, Shenyang 110001, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shenyang Tenth People\u2019s Hospital, Shenyang 110044, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendong","family":"Li","sequence":"additional","affiliation":[{"name":"Radiology Department, People\u2019s Hospital of China Medical University, Shenyang 110016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuesong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, People\u2019s Hospital of China Medical University, Shenyang 110016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, People\u2019s Hospital of China Medical University, The People\u2019s Hospital of Liaoning Province, Shenyang 110016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: Current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Barone, B., Calogero, A., Scafuri, L., Ferro, M., Lucarelli, G., Di Zazzo, E., Sicignano, E., Falcone, A., Romano, L., and De Luca, L. (2022). Immune Checkpoint Inhibitors as a Neoadjuvant\/Adjuvant Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review. Cancers, 14.","DOI":"10.3390\/cancers14102545"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1056\/NEJMp1510079","article-title":"Releasing the Brakes on Cancer Immunotherapy","volume":"373","author":"Ribas","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100011","DOI":"10.1016\/j.esmoop.2020.100011","article-title":"How we treat endocrine complications of immune checkpoint inhibitors","volume":"6","author":"Paschou","year":"2021","journal-title":"ESMO Open"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40364-020-00250-z","article-title":"Recent updates on Sintilimab in solid tumor immunotherapy","volume":"8","author":"Liu","year":"2020","journal-title":"Biomark. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.humpath.2016.09.003","article-title":"Share Immune-checkpoint status in penile squamous cell carcinoma: A North American cohort","volume":"59","author":"Cocks","year":"2017","journal-title":"Hum. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40487-020-00135-z","article-title":"Recent Advances in the Management of Penile Cancer: A Contemporary Review of the Literature","volume":"9","author":"Stecca","year":"2021","journal-title":"Oncol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000495251","article-title":"No Evidence of Microsatellite Instability and Loss of Mismatch-Repair-Protein Expression in Squamous Cell Carcinoma of the Penis","volume":"86","author":"Stoehr","year":"2019","journal-title":"Pathobiology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/jcph.1804","article-title":"Endocrine Adverse Events Caused by Different Types and Different Doses of Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A Meta-Analysis and Systematic Review","volume":"61","author":"Yang","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/1078155220922602","article-title":"Metastatic penile squamous cell carcinoma with dramatic response to combined checkpoint blockade with ipilimumab and nivolumab","volume":"27","author":"Baweja","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/CJI.0000000000000221","article-title":"Evidence for Efficacy of Treatment With the Anti-PD-1 Mab Nivolumab in Radiation and Multichemorefractory Advanced Penile Squamous Cell Carcinoma","volume":"41","author":"Trafalis","year":"2018","journal-title":"J. Immunother."},{"key":"ref_13","first-page":"8349793","article-title":"Treating Penile Cancer in the Immunotherapy and Targeted Therapy Era","volume":"2019","author":"Hui","year":"2019","journal-title":"Case Rep. Oncol. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"615298","DOI":"10.3389\/fonc.2020.615298","article-title":"Case Report: Two Cases of Chemotherapy Refractory Metastatic Penile Squamous Cell Carcinoma With Extreme Durable Response to Pembrolizumab","volume":"10","author":"Chahoud","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s10637-021-01100-x","article-title":"Pembrolizumab for advanced penile cancer: A case series from a phase II basket trial","volume":"39","author":"Hahn","year":"2021","journal-title":"Investig. New Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1159\/000517008","article-title":"Cemiplimab for Cisplatin Resistant Metastatic Penile Cancer","volume":"14","author":"Denis","year":"2021","journal-title":"Case Rep. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.2147\/OTT.S231258","article-title":"Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review","volume":"13","author":"Su","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.2147\/OTT.S319932","article-title":"Multimodal Treatment Combining Salvage Surgery-Assisted Chemotherapy and Checkpoints Blockade Immunotherapy Achieves Complete Remission on a Recurrent Penile Cancer Patient: A Case Report","volume":"14","author":"Hu","year":"2021","journal-title":"OncoTargets Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"837547","DOI":"10.3389\/fonc.2022.837547","article-title":"Immunotherapy Combined With Chemotherapy for Postoperative Recurrent Penile Squamous Cell Carcinoma: A Case Report and Literature Review","volume":"12","author":"Li","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"823459","DOI":"10.3389\/fonc.2022.823459","article-title":"Efficacy and Biomarker Exploration of Sintilimab Combined With Chemotherapy in the Treatment of Advanced Penile Squamous Cell Carcinoma\u2014A Report of Two Cases","volume":"12","author":"Mei","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed Cell Death-1 Inhibitor\u2013Induced Type 1 Diabetes Mellitus","volume":"103","author":"Clotman","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.21037\/tlcr-20-408","article-title":"Development of autoimmune diabetes with severe diabetic ketoacidosis and immune-related thyroiditis secondary to durvalumab: A case report","volume":"9","author":"Lopes","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Muniz, T.P., Araujo, D.V., Savage, K.J., Cheng, T., Saha, M., Song, X., Gill, S., Monzon, J.G., Grenier, D., and Genta, S. (2021). CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus. Cancers, 14.","DOI":"10.3390\/cancers14010089"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: A case report and systematic review","volume":"181","author":"Pen","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00125-009-1539-9","article-title":"Committee on Type 1 Diabetes, Japan Diabetes Society. Differential association of HLA with three subtypes of type 1 diabetes: Fulminant, slowly progressive and acute-onset","volume":"52","author":"Kawabata","year":"2009","journal-title":"Diabetologia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1016\/S0140-6736(16)30582-7","article-title":"Genetic risk factors for type 1 diabetes","volume":"387","author":"Pociot","year":"2016","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1097\/CM9.0000000000000972","article-title":"Type 1 diabetes induced by immune checkpoint inhibitors","volume":"133","author":"Zhang","year":"2020","journal-title":"Chin. Med. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/dme.14050","article-title":"Immune checkpoint inhibitor-induced Type 1 diabetes: A systematic review and meta-analysis","volume":"36","author":"Akturk","year":"2019","journal-title":"Diabet. Med."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/11\/632\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:02:03Z","timestamp":1760144523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/11\/632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["curroncol29110632"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29110632","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202207.0296.v1","asserted-by":"object"}]},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,25]]}}}